Alexander Kapp (dermatologist and allergist)

An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative

Retrieved on: 
Tuesday, August 15, 2023

Moreover, Dupixent continues to enjoy a unique position as the only advanced treatment for EoE.

Key Points: 
  • Moreover, Dupixent continues to enjoy a unique position as the only advanced treatment for EoE.
  • Consequently, an unlikely candidate has emerged as the next significant advancement in EoE, potentially landing the coveted second-to-market position.
  • APT-1011, a reformulation of the commonly used EoE treatment fluticasone, achieved significant improvements in both histologic and symptomatic endpoints.
  • Speaking with physicians in depth, Spherix explored the benefits and implications of APT-1011 when compared to the gold standard EoE treatment, Dupixent.

Sanofi/Regeneron's Dupixent Performance in Eosinophilic Esophagitis is Paving the Way for Future Therapies in an Underserved and Growing Market, According to Spherix Global Insights

Retrieved on: 
Tuesday, April 4, 2023

EXTON, Pa., April 3, 2023 /PRNewswire/ -- In 2017, Sanofi/Regeneron announced the FDA approval for the first biologic agent to treat atopic dermatitis (AD). The success of that drug, Dupixent (dupilumab), inspired competitors to scramble for a place in the AD market, with the second drug arriving nearly five years later. Sanofi/Regeneron followed with indications in asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (EoE) and most recently prurigo nodularis.

Key Points: 
  • Sanofi/Regeneron followed with indications in asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (EoE) and most recently prurigo nodularis.
  • The May 2022 approval of Dupixent for EoE opened the door to another untapped market, with the closest competitor entry likely several years away.
  • Spherix will continue to track the performance of Dupixent's launch for the first eighteen months on the market.
  • Performance to date suggests Dupixent will continue to carve out a commanding ownership of the advanced treatment market in EoE, while also paving the way for future competitors to meet the needs of this underserved, growing market.

Allergy Diagnostics Global Market Report 2022: Rising Air Pollution Fuels Rapid Sector Expansion - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023

According to the report, 'Allergy Diagnostics Market,' the allergy diagnostics market size was valued at $5 billion in 2021, and is estimated to reach $16.7 billion by 2031, growing at a CAGR of 13.2% from 2022 to 2031.

Key Points: 
  • According to the report, 'Allergy Diagnostics Market,' the allergy diagnostics market size was valued at $5 billion in 2021, and is estimated to reach $16.7 billion by 2031, growing at a CAGR of 13.2% from 2022 to 2031.
  • The global market for allergy diagnostics is expanding dramatically, mostly as a result of rising air pollution that can lead to chronic respiratory illnesses.
  • In addition, several studies have shown a connection between air pollution and allergic rhinitis, asthma, and other conditions, which is fueling the expansion of the allergy diagnostics market growth.
  • Due to the rapid expansion of the global allergy diagnostics industry, researchers and scientists have accelerated their R&D efforts to create cutting-edge technological gadgets for better allergy diagnostic usage on mobile phones.

Revolo Biotherapeutics To Present New Data at 2022 AAAAI Annual Meeting Demonstrating the Anti-inflammatory Effect of ‘1104 in Acute Respiratory Distress Syndrome

Retrieved on: 
Friday, February 25, 2022

The data demonstrate a marked anti-inflammatory effect of Revolos immune-resetting drug candidate, IRL201104, or 1104, and its clinical potential to treat the hyperinflammation associated with Acute Respiratory Distress Syndrome (ARDS), a leading cause of mortality in respiratory infections.

Key Points: 
  • The data demonstrate a marked anti-inflammatory effect of Revolos immune-resetting drug candidate, IRL201104, or 1104, and its clinical potential to treat the hyperinflammation associated with Acute Respiratory Distress Syndrome (ARDS), a leading cause of mortality in respiratory infections.
  • Summary: 1104 showed a marked anti-inflammatory effect to treatment which was comparable with current standard of care with the steroid dexamethasone in a murine model.
  • We believe 1104 may represent an effective, and safer alternative for the treatment of ARDS, by preventing neutrophil recruitment without inducing immunosuppression.
  • Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries.

Tarsus Medical Group Officially Announces Rebrand of South Beach Symposium to LiVDerm

Retrieved on: 
Tuesday, December 14, 2021

The new brand, LiVDerm will encompass the long-standing and revered South Beach Symposium (SBS) and Masters of Pediatric Dermatology (MOPD) events, while growing its audience beyond South Florida and opening opportunities for new functional areas of education and expanded practitioner specialties.

Key Points: 
  • The new brand, LiVDerm will encompass the long-standing and revered South Beach Symposium (SBS) and Masters of Pediatric Dermatology (MOPD) events, while growing its audience beyond South Florida and opening opportunities for new functional areas of education and expanded practitioner specialties.
  • As the name South Beach Symposium suggests, SBS and MOPD are held every year in Miami Beach, Florida, and focus on trending topics in dermatology - inflammatory disorders, hair restoration, facial fillers and rejuvenation, acne treatment, plastic surgery, pediatric skin conditions, and more.
  • Led by world-renowned experts in medical, aesthetic, and pediatric dermatology, LiVDerm empowers providers to educate, collaborate, and engage.
  • With a multipronged approach to mastering the myriad of subspecialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.

The Foundation for Dermatology Education to Host the 3rd Annual Live Revolutionizing Atopic Dermatitis (RAD) Conference - Saturday, December 11 - Monday, December 13, 2021

Retrieved on: 
Tuesday, October 19, 2021

Registration is now open for this 19.5 CME and CNE credited conference - RevolutionizingAD.com .

Key Points: 
  • Registration is now open for this 19.5 CME and CNE credited conference - RevolutionizingAD.com .
  • "The Annual Live RAD Conference offers great opportunities to hear about emerging therapies and industry 'hot topics'from the best in the field."
  • New to this year's Conference, the Totally "RAD" Award recognizes a healthcare provider in the dermatology field who has provided invaluable impact to patient care or research of AD.
  • Follow the RAD Conference on the following social media sites: